A Single-cell Approach to Identify Biomarkers of Pulmonary Toxicity for Immune Checkpoint Blockade
Universitaire Ziekenhuizen KU Leuven
60 participants
Feb 1, 2020
OBSERVATIONAL
Conditions
Summary
The main goal of this prospective non-interventional exploratory monocentric study is to characterize the immune cell composition of bronchoalveolar lavage (BAL) fluid from cancer patients experiencing cancer therapy-induced pneumonitis on a single-cell scale. These mechanistic insights can directly lead to putative diagnostic biomarkers and therapeutic targets. A second highly clinically relevant hypothesis is that single-cell profiling of blood samples will reveal circulating biomarkers of ICB toxicity, making non-invasive diagnosis feasible.
Eligibility
Inclusion Criteria5
- Adult M/F/X (>= 18 years)
- Patients receiving or having received treatment per guidelines
- Patients undergoing bronchoscopy with BAL, for possible cancer treatment-induced pneumonitis
- Not included in other clinical trials
- Signed informed consent form
Exclusion Criteria1
- Collected material not suitable for further processing in this study (e.g. bad quality). This decision will be made in consultation with a lab technician and/or bio-informatician, specialized in single-cell analysis.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
ICI, administered as standard-of-care treatment
TKI, administered as standard-of-care treatment
RT, administered as standard-of-care treatment
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04807127